No article text was recorded for this version.
fragment-based drug discovery
Version 1 of 135 papers52 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping
- Blog: Streamlining Computational Fragment-Based Drug Discovery through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening
- Blog: Structure-guided, target-based drug discovery – exploiting genome information from HIV to mycobacterial infections
- Blog: Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification
- Blog: Multi-Granular Contrastive Alignment and Fusion for Fragment-Enhanced Virtual Screening
- Blog: Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry
- Blog: Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
- Blog: A New Fragment‐Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS‐CoV‐2 NSP13 Helicase
- Blog: A Personal History of Using Crystals and Crystallography to Understand Biology and Advanced Drug Discovery
- Blog: Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery
- Blog: Small‐Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases
- Blog: Selective Aurora A-TPX2 Interaction Inhibitors Have <i>In Vivo</i> Efficacy as Targeted Antimitotic Agents
- Blog: Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding
- Blog: Structural Characterization of Mycobacterium abscessus Phosphopantetheine Adenylyl Transferase Ligand Interactions: Implications for Fragment-Based Drug Design
- Blog: A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain
- Blog: Partial-occupancy binders identified by the Pan-Dataset Density Analysis method offer new chemical opportunities and reveal cryptic binding sites
- Blog: FragmentGPT: A Unified GPT Model for Fragment Growing, Linking, and Merging in Molecular Design
- Blog: Identification of new allosteric sites and modulators of AChE through computational and experimental tools
- Blog: FMCA-DTI: a fragment-oriented method based on a multihead cross attention mechanism to improve drug–target interaction prediction
- Blog: Computational maturation of a single-domain antibody against Aβ42 aggregation
- Blog: Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic disease and antibiotic resistance
- Blog: A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer’s disease
- Blog: Structure-Guided Computational Approaches to Unravel Druggable Proteomic Landscape of Mycobacterium leprae
- Blog: How does a small molecule bind at a cryptic binding site?
- Blog: The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery
- Blog: A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis
- Blog: Flexibility and small pockets at protein–protein interfaces: New insights into druggability
- Blog: Parameter for Process Validation of Sevelamer Hydrochloride Film Coated Tablet
- Blog: Druggable binding sites in the multicomponent assemblies that characterise DNA double-strand-break repair through non-homologous end joining
- Blog: Drugging the Undruggable: Benchmarking and Modeling Fragment-Based Screening
- Blog: Protein Sequence Alignment Algorithm Based on Hybrid Profile Information
- Blog: Genomics, Computational Biology and Drug Discovery for Mycobacterial Infections: Fighting the Emergence of Resistance
- Blog: Discovery of a ROCK inhibitor, FPND, which prevents cerebral hemorrhage through maintaining vascular integrity by interference with VE-cadherin
- Blog: Incorporating Target-Specific Pharmacophoric Information into Deep Generative Models for Fragment Elaboration
- Blog: Hotspot-Driven Peptide Design via Multi-Fragment Autoregressive Extension
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_fragment_based_drug_discovery_2a73cb28,
title = {fragment-based drug discovery},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/fragment-based-drug-discovery/rdr_2a73cb28381a47e5935eeedab9ea0b89},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 1, frozen text):
@misc{lacuna_fragment_based_drug_discovery_2a73cb28_v1,
title = {fragment-based drug discovery},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/fragment-based-drug-discovery/rdr_2a73cb28381a47e5935eeedab9ea0b89/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}